U nas zapłacisz kartą
Brymonidyna na twarz - Tajemnicze Piękno Naturalnej Pielęgnacji
Case Presentation
At a physical examination, the child was drowsy and rousable for brief moments with persistent crying, hypotonia, and bilateral miosis. Upon palpation of the skull, no swellings or bony steps were observed. The child had pinkish, pale skin, a pernicious, diffusely harsh vesicular murmur in the chest with good air penetration, and strong and rhythmic cardiac activity. Her abdomen was treatable. She was afebrile, with an SpO2 of 99% in room air, an ABP of 99/51 mmHg, and a heart rate of 113/min.
In an attempt to identify a possible toxic agent, the parents were asked to check the home environment within the child’s reach. Later on, the mother reported that the vials of brimonidine-based eye drops used by the grandfather were found empty on the sofa near where the little girl had been playing.
RESULTS
Representative pictures of a mouse from each group. (A) Group 1: 1% brimonidine cream before UVR. (B) Group 2: 0.33% brimonidine gel before UVR. C) Group 3: 1% brimonidine cream after UVR. (D) Group 4: UVR, no drug treatment (UVR control). (E) Group 5: 1% brimonidine cream without UVR. (F) The mice from Group 1 and 5 developed erythema after the application of 1% brimonidine cream.
(a) Representative SCC on the back of a UVR control mouse. (b) Overview histology picture (H&E staining) (c). Close up of SCC keratin pearls.
Kaplan–Meier plot showing the probability of survival without a tumor of at least 1 mm in diameter for the groups treated with 1% brimonidine cream before UVR (Group 1), 0.33% brimonidine gel before UVR (Group 2), 1% brimonidine cream after UVR (Group 3) and UVR alone (Group 4). No tumors developed in the nonirradiated Group 5. Panels: (a) first tumor, (b) second tumor, and (c) third tumor.
References
1. Cantor L.B. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert. Opin. Pharmacother. 2000, 1 :815–834. doi: 10.1517/14656566.1.4.815. [PubMed] [CrossRef] [Google Scholar]
2. Lusthaus J.A., Goldberg I. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension, a safety evaluation. Expert. Opin. Drug Saf. 2017, 16 :1071–1078. doi: 10.1080/14740338.2017.1346083. [PubMed] [CrossRef] [Google Scholar]
3. Kingman S. Glaucoma is second leading cause of blindness globally. Bull. World Health Organ. 2004, 82 :887. [PMC free article] [PubMed] [Google Scholar]
4. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014, 121 :2081. doi: 10.1016/j.ophtha.2014.05.013. [PubMed] [CrossRef] [Google Scholar]
5. Kapetanakis V.V., Chan M.P.Y., Foster P.J., Cook D.G., Owen C.G., Rudnicka A.R. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): A systematic review and meta-analysis. Br. J. Ophthalmol. 2016, 100 :86. doi: 10.1136/bjophthalmol-2015-307223. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Mukesh B.N., McCarty C.A., Rait J.L., Taylor H.R. Five-year incidence of open-angle glaucoma: The visual impairment project. Ophthalmology. 2002, 109 :1047. doi: 10.1016/S0161-6420(02)01040-0. [PubMed] [CrossRef] [Google Scholar]
7. Leske M.C., Heijl A., Hyman L., Bengtsson B., Dong L., Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007, 114 :1965. doi: 10.1016/j.ophtha.2007.03.016. [PubMed] [CrossRef] [Google Scholar]
8. Chauhan B.C., Mikelberg F.S., Balaszi A.G., LeBlanc R.P., Lesk M.R., Trope G.E., Canadian Glaucoma Study Group Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch. Ophthalmol. 2008, 126 :1030. doi: 10.1001/archopht.126.8.1030. [PubMed] [CrossRef] [Google Scholar]
Introduction
Brimonidine is a selective alpha-2 adrenergic agonist, with a 1780-fold selectivity for α2- vs. α1-adrenergic receptors [1], and is increasingly used for the treatment of open-angle glaucoma (OAG) in children and adults [2]. After cataracts, glaucoma is the second leading cause of blindness in the world [3]. Open-angle glaucoma is the most common type of glaucoma among White and Black populations [3,4]. The estimated number of people with open-angle glaucoma in 2015 was 57.5 million, and this number was projected to increase to 65.5 million by 2020 [5]. The incidence of open-angle glaucoma increases with age, particularly in White and Black patients [6,7,8]. The prevalence of open-angle glaucoma is
Brimonidine is reported to be up to 12-fold more alpha-2-selective than clonidine and up to 32-fold more alpha-2-selective than apraclonidine (p-aminoclonidine) [10].
Brimonidine lowers intraocular pressure through a dual mechanism. It inhibits adenylyl cyclase with a decrease in cyclic adenosine monophosphate (AMP) levels and noradrenaline release through alpha-2 receptor activation, thus reducing aqueous humor production [11] and stimulating the outflow of aqueous humor via the uveoscleral pathway [12]. This latter mechanism is responsible for the drug effect following chronic treatment [13]. Although more polar and less lipophilic than clonidine ( Figure 1 ), brimonidine is known to cross the blood–brain barrier [14].
There are only limited data on the safety of brimonidine for children. The initial clinical trials mainly involved patients aged 2–7 years with a diagnosis of glaucoma, and no trials enrolled patients aged less than 1 year [10]. However, as it does not cause reduced pulmonary function and heart rate (HR), unlike β-adrenergic blocking agents, it is licensed for use in children over 5 years old [20]. Yet, a child’s lower weight could make the patient more susceptible to complications, thus, the pediatric age group is at greater risk [21,22]. In Italy, brimonidine administration to children aged 2 to 12 years is not recommended.